← Holders
RA Capital Management, L.P.
What RA Capital Management, L.P. reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 1346824 · Filed Nov 16, 2026
- Positions
- 92
- Reported value
- $10B
- Opened
- 21
- Closed
- 13
- Other managers included
- 0
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
Quarters on file
- Sep 30, 2025$8.1B67 positions
- Dec 31, 2025$9.8B71 positions
- Mar 31, 2026$9.4B85 positions
- Jun 30, 2026$11.5B84 positions
- Sep 30, 2026$10B92 positions
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
ASNDAscendis Pharma A/S | 10.3M | ±0% | $2.3B | 23.5% |
PBLSParabilis Medicines, Inc. | 29.2M | +0.8% | $942.2M | 9.5% |
PCVXVaxcyte, Inc. | 11.5M | ±0% | $652.9M | 6.5% |
RYTMRhythm Pharmaceuticals, Inc. | 6.7M | ±0% | $634.8M | 6.4% |
EWTXEdgewise Therapeutics, Inc. | 8.4M | ±0% | $340.7M | 3.4% |
TYRATyra Biosciences, Inc. | 12.2M | ±0% | $266.8M | 2.7% |
FRNMFreenome, Inc. | 15.4M | New | $242M | 2.4% |
COAGHemab Therapeutics Holdings, Inc. | 7.8M | ±0% | $240.8M | 2.4% |
NAMSNewAmsterdam Pharma Co N.V. | 9.6M | ±0% | $232.3M | 2.3% |
SEPNSepterna, Inc. | 5.5M | −21.3% | $215.3M | 2.2% |
SGPSpyGlass Pharma, Inc. | 8M | ±0% | $208.5M | 2.1% |
JANXJanux Therapeutics, Inc. | 11.2M | ±0% | $193.4M | 1.9% |
MLYSMineralys Therapeutics, Inc. | 7.7M | ±0% | $193.3M | 1.9% |
IRONDisc Medicine, Inc. | 2.5M | ±0% | $160.4M | 1.6% |
TSHATaysha Gene Therapies, Inc. | 30.4M | +29.2% | $148.2M | 1.5% |
BCAXBicara Therapeutics Inc. | 7.3M | ±0% | $135M | 1.4% |
ARTVArtiva Biotherapeutics, Inc. | 18.5M | +3.0% | $131.6M | 1.3% |
XNCRXencor Inc | 5.3M | ±0% | $131.6M | 1.3% |
ORKAOruka Therapeutics, Inc. | 1.6M | ±0% | $129.5M | 1.3% |
AMLXAmylyx Pharmaceuticals, Inc. | 4.3M | New | $124.5M | 1.2% |
CLYMClimb Bio, Inc. | 10.1M | −10.4% | $116.2M | 1.2% |
ABVXAbivax S.A. | 1M | −9.1% | $102M | 1% |
WVEWave Life Sciences, Inc. | 27M | New | $99.8M | 1% |
LTGOLatigo Biotherapeutics, Inc. | 5.3M | New | $88.6M | 0.9% |
SLDBSolid Biosciences Inc. | 12M | ±0% | $87M | 0.9% |
VORVor Biopharma Inc. | 4.5M | +87.5% | $85.9M | 0.9% |
LBRXLB Pharmaceuticals Inc | 2.2M | ±0% | $84.8M | 0.9% |
GHRSGH Research PLC | 3.6M | −52.7% | $84.7M | 0.9% |
OBXObsidian Therapeutics, Inc. | 6M | New | $81.8M | 0.8% |
ZLABZai Lab Ltd | 2.8M | −51.0% | $74.2M | 0.7% |
FDMT4D Molecular Therapeutics, Inc. | 5M | ±0% | $72.3M | 0.7% |
ACRSAclaris Therapeutics, Inc. | 12.7M | ±0% | $66.9M | 0.7% |
SANASana Biotechnology, Inc. | 18.8M | ±0% | $54.7M | 0.5% |
MNPRMonopar Therapeutics | 667.2K | ±0% | $53.2M | 0.5% |
GERNGeron Corp | 42.8M | −0.1% | $52.6M | 0.5% |
DMRADamora Therapeutics, Inc. | 2.4M | New | $51.1M | 0.5% |
PEPGPepGen Inc. | 20.1M | ±0% | $48.6M | 0.5% |
SPRYARS Pharmaceuticals, Inc. | 10.9M | ±0% | $46.8M | 0.5% |
ABOSAcumen Pharmaceuticals, Inc. | 21M | ±0% | $46.6M | 0.5% |
DBVTDBV Technologies S.A. | 3.7M | New | $43M | 0.4% |
AGENAgenus Inc | 4.1M | New | $40.9M | 0.4% |
RZLTRezolute, Inc. | 9.4M | ±0% | $39.1M | 0.4% |
SIONSionna Therapeutics, Inc. | 6.5M | −34.8% | $34M | 0.3% |
SCTXScribe Therapeutics, Inc. | 1.8M | New | $33.2M | 0.3% |
IPSCCentury Therapeutics, Inc. | 17.8M | ±0% | $30.4M | 0.3% |
EVMNEvommune, Inc. | 3.5M | ±0% | $28.9M | 0.3% |
KRSAKorsana Biosciences, Inc. | 892.7K | New | $28.6M | 0.3% |
CAPRCapricor Therapeutics, Inc. | 3M | +99.9% | $28.5M | 0.3% |
NKTXNkarta, Inc. | 10.8M | ±0% | $28.3M | 0.3% |
CCCCC4 Therapeutics, Inc. | 8.2M | +2.4% | $27.3M | 0.3% |
JBIOJade Biosciences, Inc. | 1.8M | −50.0% | $25.8M | 0.3% |
PRLDPrelude Therapeutics Inc | 6.5M | ±0% | $25.3M | 0.3% |
ACRVAcrivon Therapeutics, Inc. | 12.2M | ±0% | $25.1M | 0.3% |
ASMBAssembly Biosciences, Inc. | 1M | ±0% | $24M | 0.2% |
EDITEditas Medicine, Inc. | 8.9M | ±0% | $22.8M | 0.2% |
QTTBQ32 Bio Inc. | 2.3M | ±0% | $19.3M | 0.2% |
AVRAnteris Technologies Global Corp. | 2.5M | −17.5% | $19.2M | 0.2% |
ETRAElectra Therapeutics, Inc. | 1.7M | New | $19M | 0.2% |
ALTAltimmune, Inc. | 6.5M | ±0% | $18.6M | 0.2% |
BNTCBenitec Biopharma Inc. | 1.9M | ±0% | $18.5M | 0.2% |
ALXOALX Oncology Holdings Inc | 13M | ±0% | $18.1M | 0.2% |
SGMTSagimet Biosciences Inc. | 1.8M | New | $17.8M | 0.2% |
LXEOLexeo Therapeutics, Inc. | 5M | ±0% | $16.9M | 0.2% |
LENZLENZ Therapeutics, Inc. | 4.2M | ±0% | $16M | 0.2% |
AURAAura Biosciences, Inc. | 2.5M | ±0% | $15.7M | 0.2% |
AVTXAvalo Therapeutics, Inc. | 1M | ±0% | $15.3M | 0.2% |
IKTInhibikase Therapeutics, Inc. | 7M | New | $14.3M | 0.1% |
ENTXEntera Bio Ltd. | 4.9M | New | $14.3M | 0.1% |
SPTXSeaport Therapeutics, Inc. | 700K | ±0% | $14.1M | 0.1% |
SABSSAB Biotherapeutics, Inc. | 4.4M | ±0% | $14M | 0.1% |
OVIDOvid Therapeutics Inc. | 5.6M | −46.7% | $13.9M | 0.1% |
MIRMMirum Pharmaceuticals, Inc. | 159.3K | −50.0% | $13.6M | 0.1% |
HLXCHelix Acquisition Corp. III | 1.3M | ±0% | $13.3M | 0.1% |
DRUGBright Minds Biosciences Inc. | 265K | ±0% | $13.2M | 0.1% |
CRBPCorbus Pharmaceuticals Holdings, Inc. | 1.9M | New | $13.1M | 0.1% |
BRVEBraveheart Bio, Inc. | 565K | New | $11.4M | 0.1% |
OKUROnKure Therapeutics, Inc. | 4M | ±0% | $10.9M | 0.1% |
PALIPalisade Bio, Inc. | 7.1M | ±0% | $9.6M | 0.1% |
INOInovio Pharmaceuticals, Inc. | 7.2M | New | $8.8M | 0.1% |
MGNXMacrogenics Inc | 1.9M | ±0% | $7.2M | 0.1% |
RANIRani Therapeutics Holdings, Inc. | 8.5M | ±0% | $6.7M | 0.1% |
ACETAdicet Bio, Inc. | 932.6K | ±0% | $6.7M | 0.1% |
TCGXTCGX Acquisition Corp. | 500K | New | $6.3M | 0.1% |
FTHFaeth Therapeutics, Inc. | 205.1K | −71.6% | $6.1M | 0.1% |
JATTJATT II Acquisition Corp. | 500K | ±0% | $5.6M | 0.1% |
JTTTJATT III Acquisition Corp | 450K | New | $5M | 0.1% |
NAMSWNewAmsterdam Pharma Co N.V. | 333.3K | ±0% | $4.2M | 0.1% |
AMANAmanat Acquisition Corp. | 375K | ±0% | $4M | 0.1% |
EQEquillium, Inc. | 2.3M | −25.1% | $3.8M | 0.1% |
STROSutro Biopharma, Inc. | 210.9K | New | $3.4M | 0.1% |
STOKStoke Therapeutics, Inc. | 73.6K | New | $1.9M | 0.1% |
PTNPalatin Technologies Inc | 62.1K | ±0% | $551K | 0.1% |